Cellular basis for atrial fibrillation in an experimental model of short QT1: Implications for a pharmacological approach to therapy

Heart Rhythm

Volumn 7, Issue 2, 2010, Pages 251-257

  Nof, Eyal ^a,b   Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiarrhythmic drugs; Arrhythmia; Electrophysiology; Isoproterenol; Quinidine

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ISOPRENALINE; LIDOCAINE; PD 118057; POTASSIUM CHANNEL STIMULATING AGENT; QUINIDINE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CYTOPATHOLOGY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOG; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; SHORT QT SYNDROME;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ANTHRANILIC ACIDS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; ELECTROCARDIOGRAPHY; ISOPROTERENOL; LIDOCAINE; QUINIDINE;

EID: 74449091136     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.10.017     Document Type: Article

References (39)

1. Viskin S., Zeltsner D., Ish-Shalom M., et al. Is idiopathic ventricular fibrillation a short QT syndrome?. Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 1 (2004) 587-591
2. Gussak I., Brugada P., Brugada J., et al. Idiopathic short QT interval: a new clinical syndrome?. Cardiology 94 (2000) 99-102
3. Gussak I., Brugada P., Brugada J., et al. ECG phenomenon of idiopathic and paradoxical short QT intervals. Cardiac Electrophysiol Rev 6 (2002) 49-53
4. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome: a familial cause of sudden death. Circulation 108 (2003) 965-970
5. Bjerregaard P., and Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2 (2005) 84-87
6. Gussak I., and Bjerregaard P. Short QT syndrome-5 years of progress. J Electrocardiol 38 (2005) 375-377
7. Brugada R., Hong K., Dumaine R., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109 (2004) 30-35
8. Bellocq C., Van Ginneken A.C., Bezzina C.R., et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109 (2004) 2394-2397
9. Priori S.G., Pandit S.V., Rivolta I., et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96 (2005) 800-807
10. Extramiana F., and Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short QT syndrome. Circulation 110 (2004) 3661-3666
11. Patel C., and Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 5 (2008) 585-590
12. Hong K., Bjerregaard P., Gussak I., and Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 16 (2005) 394-396
13. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 43 (2004) 1494-1499
14. Giustetto C., Di Monte F., Wolpert C., et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 27 (2006) 2440-2447
15. Poglajen G., Fister M., Radovancevic B., and Vrtovec B. Short QT interval and atrial fibrillation in patients without structural heart disease. J Am Coll Cardiol 47 (2006) 1905-1907
16. Bosch R.F., Zeng X., Grammer J.B., et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44 (1999) 121-131
17. Atienza F., Almendral J., Moreno J., et al. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism. Circulation 114 (2006) 2434-2442
18. Chen Y.H., Xu S.J., Bendahhou S., et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299 (2003) 251-254
19. Yang Y., Xia M., Jin Q., et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 75 (2004) 899-905
20. Lundby A., Ravn L.S., Svendsen J.H., Olesen S.P., and Schmitt N. KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval. Heart Rhythm 4 (2007) 1532-1541
21. Schuessler R.B., Kawamoto T., Hand D.E., et al. Simultaneous epicardial and endocardial activation sequence mapping in the isolated canine right atrium. Circulation 88 (1993) 250-263
22. Kur block. Am J Physiol 286 (2004) H2393-H2400
23. Feng J., Yue L., Wang Z., and Nattel S. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res 83 (1998) 541-551
24. Haissaguerre M., Sanders P., Hocini M., et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 16 (2005) 1125-1137
25. Tsai C.F., Tai C.T., Hsieh M.H., et al. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation 102 (2000) 67-74
26. Sanders P., Berenfeld O., Hocini M., et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation 112 (2005) 789-797
27. Liu L., and Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol 273 (1997) H805-H816
28. Sharifov O.F., Fedorov V.V., Beloshapko G.G., et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol 43 (2004) 483-490
29. Burashnikov A., and Antzelevitch C. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation?. J Atrial Fibrillation 1 (2008) 98-107
30. Burashnikov A., and Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol 14 (2009) 290-300
31. Burashnikov A., Di Diego J.M., Sicouri S., et al. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm 5 (2008) 1735-1742
32. Wolpert C., Schimpf R., Giustetto C., et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 16 (2005) 54-58
33. Antzelevitch C., Pollevick G.D., Cordeiro J.M., et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115 (2007) 442-449
34. Rivard L., Sinno H., Shiroshita-Takeshita A., et al. The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. Cardiovasc Res 74 (2007) 104-113
35. Blaauw Y., Gogelein H., Tieleman R.G., et al. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110 (2004) 1717-1724
36. Duytschaever M., Blaauw Y., and Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 67 (2005) 69-76
37. Marrouche N.F., Reddy R.K., Wittkowsky A.K., and Bardy G.H. High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial. Am Heart J 139 (2000) E8-E11
38. + channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 41 (2006) 563-566
39. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 67 (2005) 498-509